Site de formation à la lecture de l'ElectroCardioGramme.

Utilisateur 

Mot de passe 
 
  Physiologie
  Technique
  Terminologie
  Arythmie SV
  Arythmie V
  Blocs
  Coronaropathie
  Cardiopathie
  Toxique/métabolique
  Traitement
  Général
 
 
 
   
 
 
 
Fibrillation atriale 8b. contrôle rythme
Figures issues des Recommandations ESC 2012 sur FA 


Figure 1. Choice of antiarrhythmic drug according to underlying pathology.

 

Key points (p. 2741)

† Rhythm-control therapy, whether by antiarrhythmic drugs or by catheter ablation, is indicated to relieve symptoms associated with AF.

 
† Antiarrhythmic drugs should not be used for rate control in patients with permanent AF, unless appropriate rate control agents fail.
 
† In selected patients, limiting antiarrhythmic drug therapy to four weeks after cardioversion may help to improve safety.
 
† In a given patient, the choice of an antiarrhythmic drug should be driven by the perceived safety of the drug. This is more important than perceived efficacy.
 
† Dronedarone is recommended in patients with recurrent AF as a moderately effective antiarrhythmic agent for the maintenance of sinus rhythm (Classe I A). Dronedarone is appropriate for maintaining sinus rhythm inpatients with paroxysmal or persistent AF. Best in case of "Minimal or no structural heart disease " ou "moderate LVH", not in permanent AF.
 
† Dronedarone should not be given to patients with moderate or severe heart failure, and should be avoided in patients with less-severe heart failure, if appropriate alternatives exist.
 

 

  

 
 
 
 
 
Dr Pierre Taboulet
Pierre Taboulet
Cardiologue
Urgentiste
Hôpital Saint-Louis (APHP)

 
Ce site est construit à partir du livre

ISBN : 978-2-224-03101-5

publié chez
Vigot-Maloine
(Ed. 2010)
 
 
Vous êtes le 11720985 visiteurs.